CA2959478C - Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis - Google Patents
Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis Download PDFInfo
- Publication number
- CA2959478C CA2959478C CA2959478A CA2959478A CA2959478C CA 2959478 C CA2959478 C CA 2959478C CA 2959478 A CA2959478 A CA 2959478A CA 2959478 A CA2959478 A CA 2959478A CA 2959478 C CA2959478 C CA 2959478C
- Authority
- CA
- Canada
- Prior art keywords
- fluoro
- compound
- chloro
- dihydroquinolin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014174528 | 2014-08-28 | ||
| JP2014-174528 | 2014-08-28 | ||
| PCT/JP2015/004371 WO2016031255A1 (en) | 2014-08-28 | 2015-08-28 | Heterobicyclic compounds and their use for the treatment of tuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2959478A1 CA2959478A1 (en) | 2016-03-03 |
| CA2959478C true CA2959478C (en) | 2023-09-26 |
Family
ID=54105947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2959478A Active CA2959478C (en) | 2014-08-28 | 2015-08-28 | Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10053446B2 (OSRAM) |
| EP (1) | EP3186240B9 (OSRAM) |
| JP (1) | JP6625612B2 (OSRAM) |
| KR (1) | KR102418413B1 (OSRAM) |
| CN (1) | CN106795117B (OSRAM) |
| AP (1) | AP2017009788A0 (OSRAM) |
| AR (1) | AR101704A1 (OSRAM) |
| AU (1) | AU2015307873B2 (OSRAM) |
| BR (1) | BR112017003231B1 (OSRAM) |
| CA (1) | CA2959478C (OSRAM) |
| CY (1) | CY1122286T1 (OSRAM) |
| DK (1) | DK3186240T3 (OSRAM) |
| EA (1) | EA038414B1 (OSRAM) |
| ES (1) | ES2743788T3 (OSRAM) |
| HR (1) | HRP20191486T2 (OSRAM) |
| HU (1) | HUE045025T2 (OSRAM) |
| IL (1) | IL250484B (OSRAM) |
| LT (1) | LT3186240T (OSRAM) |
| MX (1) | MX2017002312A (OSRAM) |
| MY (1) | MY189098A (OSRAM) |
| NZ (1) | NZ729064A (OSRAM) |
| PH (1) | PH12017500290B1 (OSRAM) |
| PL (1) | PL3186240T3 (OSRAM) |
| PT (1) | PT3186240T (OSRAM) |
| SG (1) | SG11201700882XA (OSRAM) |
| SI (1) | SI3186240T1 (OSRAM) |
| TW (1) | TWI687409B (OSRAM) |
| WO (1) | WO2016031255A1 (OSRAM) |
| ZA (1) | ZA201700916B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101704A1 (es) * | 2014-08-28 | 2017-01-04 | Otsuka Pharma Co Ltd | Compuestos heterocíclicos fusionados |
| WO2017146246A1 (ja) * | 2016-02-26 | 2017-08-31 | 大塚製薬株式会社 | ピペリジン誘導体 |
| US20210292333A1 (en) | 2018-06-15 | 2021-09-23 | Cadila Healthcare Limited | Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria |
| JP2023085582A (ja) * | 2020-05-11 | 2023-06-21 | 大塚製薬株式会社 | ジヒドロキノリノン化合物の共結晶 |
| EP4201407A4 (en) * | 2020-08-19 | 2024-07-31 | MitoImmune Therapeutics Inc. | ANTIOXIDANT TARGETING MITOCHONDRIA AS AN AGENT FOR THE TREATMENT OF PATHOLOGICAL INFLAMMATION CAUSED BY MABC-R INFECTION |
| CN116102537B (zh) * | 2021-11-10 | 2024-10-01 | 四川大学 | 一种喹啉酮类衍生物及其制备方法和用途 |
| CN116589448B (zh) * | 2023-04-24 | 2025-10-28 | 西南交通大学 | 一种3,4-二氢喹啉酮衍生物及其应用 |
| WO2025183016A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
| WO2025183017A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5668127A (en) | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
| TWI347946B (en) | 2002-10-11 | 2011-09-01 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound |
| GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| ZA200602184B (en) * | 2003-10-31 | 2007-10-31 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis |
| WO2005042542A1 (en) | 2003-10-31 | 2005-05-12 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis |
| JP4761756B2 (ja) | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 |
| CN101891680B (zh) * | 2004-06-24 | 2014-10-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| WO2007099828A1 (ja) | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| WO2010045987A1 (en) * | 2008-10-23 | 2010-04-29 | Glaxo Group Limited | Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials |
| EP2459570B1 (en) | 2009-07-31 | 2014-12-24 | Global Alliance For Tb Drug Development | Nitroimidazooxazine analogues and their uses |
| EP2697232B1 (en) | 2011-04-15 | 2016-05-18 | Otsuka Pharmaceutical Co., Ltd. | 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides |
| AR101704A1 (es) * | 2014-08-28 | 2017-01-04 | Otsuka Pharma Co Ltd | Compuestos heterocíclicos fusionados |
| WO2017146246A1 (ja) * | 2016-02-26 | 2017-08-31 | 大塚製薬株式会社 | ピペリジン誘導体 |
-
2015
- 2015-08-27 AR ARP150102746A patent/AR101704A1/es active IP Right Grant
- 2015-08-27 TW TW104128109A patent/TWI687409B/zh active
- 2015-08-28 CA CA2959478A patent/CA2959478C/en active Active
- 2015-08-28 AP AP2017009788A patent/AP2017009788A0/en unknown
- 2015-08-28 PH PH1/2017/500290A patent/PH12017500290B1/en unknown
- 2015-08-28 US US15/506,887 patent/US10053446B2/en active Active
- 2015-08-28 SG SG11201700882XA patent/SG11201700882XA/en unknown
- 2015-08-28 MX MX2017002312A patent/MX2017002312A/es active IP Right Grant
- 2015-08-28 HU HUE15763096A patent/HUE045025T2/hu unknown
- 2015-08-28 SI SI201530868T patent/SI3186240T1/sl unknown
- 2015-08-28 EP EP15763096.3A patent/EP3186240B9/en active Active
- 2015-08-28 DK DK15763096.3T patent/DK3186240T3/da active
- 2015-08-28 CN CN201580045974.4A patent/CN106795117B/zh active Active
- 2015-08-28 AU AU2015307873A patent/AU2015307873B2/en active Active
- 2015-08-28 BR BR112017003231-7A patent/BR112017003231B1/pt active IP Right Grant
- 2015-08-28 LT LTEP15763096.3T patent/LT3186240T/lt unknown
- 2015-08-28 ES ES15763096T patent/ES2743788T3/es active Active
- 2015-08-28 PT PT15763096T patent/PT3186240T/pt unknown
- 2015-08-28 WO PCT/JP2015/004371 patent/WO2016031255A1/en not_active Ceased
- 2015-08-28 HR HRP20191486TT patent/HRP20191486T2/hr unknown
- 2015-08-28 PL PL15763096T patent/PL3186240T3/pl unknown
- 2015-08-28 JP JP2017507903A patent/JP6625612B2/ja active Active
- 2015-08-28 NZ NZ729064A patent/NZ729064A/en unknown
- 2015-08-28 MY MYPI2017700649A patent/MY189098A/en unknown
- 2015-08-28 KR KR1020177007855A patent/KR102418413B1/ko active Active
- 2015-08-28 EA EA201790464A patent/EA038414B1/ru unknown
-
2017
- 2017-02-06 ZA ZA2017/00916A patent/ZA201700916B/en unknown
- 2017-02-07 IL IL250484A patent/IL250484B/en active IP Right Grant
-
2018
- 2018-07-09 US US16/029,850 patent/US10464926B2/en active Active
-
2019
- 2019-08-26 CY CY20191100906T patent/CY1122286T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10464926B2 (en) | Heterobicyclic compounds and their use for the treatment of tuberculosis | |
| CN103003233B (zh) | 新型异羟肟酸衍生物 | |
| CA3172478A1 (en) | Bcl-2 inhibitor | |
| CA2927798C (en) | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | |
| US12319672B2 (en) | Alpha-D-galactopyranoside derivatives | |
| US8822460B2 (en) | Fused cyclopentyl antagonists of CCR2 | |
| US10669283B2 (en) | Compound and pharmacologically acceptable salt thereof | |
| CN114206893A (zh) | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 | |
| RO108867B1 (ro) | Derivati de piridazinamine, procedee si intermediari pentru prepararea lor | |
| TW202024056A (zh) | 作為ccr6抑制劑之n取代二氧代環丁烯基胺基-3-羥基-吡啶醯胺 | |
| US20080275035A1 (en) | Nitroimidazole Compounds | |
| ES2553387T3 (es) | Compuestos heterocíclicos para el tratamiento o la prevención de trastornos causados por neurotransmisión reducida de serotonina, norepinefrina o dopamina | |
| JP6976691B2 (ja) | 医薬組成物 | |
| OA18228A (en) | Heterobicyclic compounds and their use for the treatment of tuberculosis. | |
| HK1239683A1 (en) | Heterobicyclic compounds and their use for the treatment of tuberculosis | |
| HK1239683B (en) | Heterobicyclic compounds and their use for the treatment of tuberculosis | |
| RU2840112C2 (ru) | Производные бензотриазола | |
| MX2008008195A (en) | Nitroimidazole compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201113 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |